References
- Cody R.J., Covit A.S., Schaer G.L., Laragh J.H. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure.J. Am. Coll. Cardiol. 1(4): 1154–1159, 1983
- Fitzpatrick D., Nicholls M.G., Ikram H., Espiner E.A. Haemodynamic, hormonal, and electrolyte effects of enalapril in heart failure. Br. Heart J. 50: 163–169, 1983
- Kramer B.L., Massie B.M., Topic N. Controlled Trial of Captopril in Chronic Heart Failure: A rest and exercise hemodynamic study. Circulation 67: 807–816, 1983
- Packer M., Medina N., Yushak M., Meller J. Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 68: 803–812, 1983
- Ulm E.H. Enalapril maleate (MK-421), a potent, nonsulfhydryl angiotensin-converting enzyme inhibitor: Absorption, disposition, and metabolism in man. Drug Metab. Rev. 14(1): 99–110, 1983
- Ulm E.H., Hichens M., Gomez H.J., Till A.E., Hand E., Vassil T.C., Biollaz J., Brunner H.R., Schelling J.L. Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br. J. Clin. Pharmacol. 14: 357–362, 1982.